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tain antibodies play a role by recruiting macrophages to the 
muscle in an ADCC process, remains unclear.
In uncontrolled studies, PM and DM respond to prednisone 
to some degree and for some period of time; adding an immuno-
suppressive drug (Azathioprine, Cyclosporine, Mycophenolate, 
Methotrexate) may have a steroid-sparing effect but their benefit 
is uncertain. In contrast, IBM is resistant to most of these thera-
pies, most times. Controlled studies have shown that IVIg is 
effective and safe for the treatment of DM. The clinical benefit, 
which can be impressive in patients with early disease, is associ-
ated with improvement in the muscle cytoarchitecture and reso-
lution of the aberrant immunopathological parameters, includ-
ing interception of complement activation and downregulation 
of ICAM-I, VCAM, TGF-β, MHC-I and various immunoregu-
latory and structural genes. IVIg seems to be also effective in 
patients with PM but offers transient help to a small number of 
patients with IBM.
New agents currently on the market may be promising new 
therapies for the treatment of inflammatory myopathies. Among 
them  include  the  monoclonal  antibodies  or  fusion  proteins 
against:  a)  molecules  associated  with  T-cell-signaling  path-
ways,  such  as  the  anti-CD52  (CAMPATH),  anti-LFA/ICAM 
(Leukocyte  Functional Antigen/  Intracellular Adhesion  Mol-
ecule), and anti-IL2 receptor (IL2-receptor antagonist). Further, 
two cytophillin-binding drugs, Tacrolimus and Rapamycin, that 
prevent the IL2-induced T cell proliferation or transcription, 
may be candidate agents for certain conditions; b) B cells using 
the monoclonal antibody directed against CD20, expressed on 
B cells (Rituximab) or the humanized version Occrelizumab; 
agents against B-cell growth factors, such as BAFF and APRIL 
are in the offing; c) Complement C5 (Eculizumab), which might 
be appropriate for some complement-mediated disorders like 
DM or NAM; d) cytokines, especially agents against TNF-α, 
IL1 or IL1β; and e) Cellular Adhesion and T cell transmigration 
molecules. Such agents include Natalizumab directed against 
a4β1 integrin (VLA4) on lymphocytes, a drug approved for 
multiple  sclerosis,  and  Fingolimod,  an  anti-T-cell-migration 
agent that traps lymphocytes in the lymphoid organs.
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Spinal muscular atrophy (SMA) is an autosomal recessive 
disorder that affects motor neurons. It is caused by mutations 
in the survival motor neuron gene 1 (SMN1). The SMN2 gene, 
which is the highly homologous SMN1 copy that is present in 
all patients, is unable to prevent the disease. SMA patients can 
be classified into four groups based on age at onset and acquired 
milestones (type I or severe acute disease, with onset before 6 
months; type II, before 18 months; type III, after 18 months and 
type IV, in adult life). The explanation for the neuromuscular 
phenotype in SMA is to assume that insufficient SMN protein 
causes motor neuron dysfunction and death, and that muscle at-
rophy is a consequence of denervation. However, investigation 
is ongoing to ascertain whether muscle, neuromuscular junc-
tions, or motor neurons alone are the critical target tissue in 
SMA. The neuropathologic description of SMA comes largely 
from postnatal necropsy samples, which describe the end-stage 
of the disease. The human developmental period appears to play 
an essential role in SMA pathogenesis. With the exception of 
severe congenital SMA (type 0), varying age at onset in the 
four SMA types provides evidence of a latency period without 
clear manifestations in most SMA patients. Given that studies 
of patients’ preclinical status are lacking, the main objective of 
our work is to study SMA during development to gain insight 
into the mechanism of disease in the prenatal and presympto-
matic  stage.  Prenatal  SMN  tests  performed  at  around  11-13 
weeks allowed us to identify fetuses predicted to develop SMA 
in families with a previous patient affected by type I disease. 
SMA fetuses were collected from therapeutic abortions after 
confirmation of a homozygous deletion of exon 7 and 8 of the 
SMN gene by chorionic villi DNA analysis. In these samples we 
systematically studied histology, cell death and gene and protein 
expression in spinal cord and muscle, the key tissues involved 
in the disease. The study of terminal peripheral nerves and neu-
romuscular junctions identify possible links between the two 
tissues in the pathogenesis of the disease. By confocal and elec-
tron microscopy we observed a variable degree of changes in 
the acetylcholine receptors clustering, presynaptic retention of 
vesicles and terminal nerve degeneration in the motor endplates 
of  fetuses  with  severe  SMA.  Furthermore,  ultrasound  fetal 
movements were investigated at these stages. At the gestational 
age examined, we did not observe a qualitative early limitation 
of movements in fetuses with SMA. Our results support the 
view of SMA as a developmental disorder and the hypothesis 
that motor neurons, terminal peripheral nerves, neuromuscular 
junctions and skeletal muscle may play all together a role in the 
pathology of SMA. These studies may help to define therapeutic 
targets and delineate a possible early intervention in SMA.
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Pathogenesis of muscle degeneration  
in periodic paralyses and DMD
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Mutations in Cav1.1 and Nav1.4 channels cause hypokale-
mic periodic paralysis, a dominantly inherited muscle disorder 
characterized  by  episodic  weakness  and  chronic  progressive 
weakness. In-vivo 23Na magnetic resonance imaging (MRI), 
fat-suppressed 1H-MRI (STIR), and force assessment were per-
formed to determine intramuscular Na+ load, edema, and mus-
cle strength in patients under different conditions. Membrane 